The US Food and Drug Administration approved Shandong Xinhua Pharmaceutical's (SHE:000756) active pharmaceutical ingredient application for sevelamer carbonate, according to a Tuesday filing with the Shenzhen Stock Exchange.
The drug is used for hyperphosphatemia or high blood phosphate levels in adults undergoing dialysis, the filing said.